Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAINASDAQ:EGHTNASDAQ:FORANASDAQ:MXCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAIArrive AI$7.61+13.2%$0.00$4.61▼$40.00$251.05MN/A2.79 million shs385,254 shsEGHT8X8$1.84$1.74$1.51▼$3.52$247.44M1.791.11 million shs1.25 million shsFORAForian$2.12+2.9%$2.04$1.85▼$4.03$66.15M1.0216,547 shs3,201 shsMXCTMaxCyte$2.11-1.9%$2.43$2.10▼$5.20$224.54M1.27614,269 shs458,715 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAIArrive AI0.00%+760,999,900.00%+760,999,900.00%+760,999,900.00%+760,999,900.00%EGHT8X80.00%+1.66%+2.22%-14.81%-2.13%FORAForian0.00%+3.92%-0.93%+2.91%-20.90%MXCTMaxCyte0.00%-7.05%-3.21%-31.72%-52.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAIArrive AIN/AN/AN/AN/AN/AN/AN/AN/AEGHT8X84.1376 of 5 stars4.05.00.00.01.92.51.9FORAForian1.7706 of 5 stars3.52.00.00.00.01.70.0MXCTMaxCyte2.5859 of 5 stars3.55.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAIArrive AI 0.00N/AN/AN/AEGHT8X8 2.00Hold$2.5136.65% UpsideFORAForian 3.00Buy$5.00135.85% UpsideMXCTMaxCyte 3.00Buy$7.50255.45% UpsideCurrent Analyst Ratings BreakdownLatest FORA, ARAI, MXCT, and EGHT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/24/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/20/2025EGHT8X8Rosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.70 ➝ $2.705/14/2025EGHT8X8B. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $3.005/10/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/24/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/24/2025EGHT8X8Rosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.30 ➝ $2.704/22/2025EGHT8X8Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$2.00 ➝ $1.504/16/2025EGHT8X8Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$2.60 ➝ $1.904/15/2025EGHT8X8MizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$2.50 ➝ $2.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAIArrive AIN/AN/AN/AN/AN/AN/AEGHT8X8$715.07M0.35$0.65 per share2.81$0.93 per share1.98FORAForian$22.33M2.96N/AN/AN/A∞MXCTMaxCyte$38.63M5.81N/AN/A$1.95 per share1.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAIArrive AIN/AN/A0.00∞N/AN/AN/AN/AN/AEGHT8X8-$27.21M-$0.2136.8018.40N/A-3.81%5.73%0.90%N/AFORAForianN/A-$0.09N/A∞N/AN/AN/AN/A8/13/2025 (Estimated)MXCTMaxCyte-$41.06M-$0.40N/AN/AN/A-110.92%-19.90%-17.24%8/5/2025 (Estimated)Latest FORA, ARAI, MXCT, and EGHT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025FORAForian$0.02-$0.04-$0.06-$0.04$5.37 million$7.06 million5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAIArrive AIN/AN/AN/AN/AN/AEGHT8X8N/AN/AN/AN/AN/AFORAForianN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAIArrive AIN/A3.80N/AEGHT8X82.771.201.20FORAForianN/AN/AN/AMXCTMaxCyteN/A12.2311.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAIArrive AIN/AEGHT8X893.99%FORAForian19.25%MXCTMaxCyte68.81%Insider OwnershipCompanyInsider OwnershipARAIArrive AIN/AEGHT8X81.22%FORAForian34.30%MXCTMaxCyte3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAIArrive AI732.99 millionN/AN/AEGHT8X81,942134.48 million132.84 millionOptionableFORAForian14031.20 millionN/AOptionableMXCTMaxCyte80106.42 million102.90 millionOptionableFORA, ARAI, MXCT, and EGHT HeadlinesRecent News About These CompaniesMaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing EfficiencyJune 12, 2025 | nasdaq.comMaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular TherapiesJune 11, 2025 | globenewswire.comMaxCyte (NASDAQ:MXCT) Rating Increased to Hold at Wall Street ZenJune 8, 2025 | marketbeat.comMaxCyte Expands Stock Capital Amidst Strategic GrowthJune 2, 2025 | tipranks.comMaxCyte (NASDAQ:MXCT) Downgraded to "Sell" Rating by Wall Street ZenJune 1, 2025 | marketbeat.comMillennium Management LLC Sells 1,451,994 Shares of MaxCyte, Inc. (NASDAQ:MXCT)May 26, 2025 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by Lazard Asset Management LLCMay 23, 2025 | marketbeat.comMaxCyte, Inc. (MXCT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comMaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comMaxCyte, Inc.: MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceMay 7, 2025 | finanznachrichten.deMaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceMay 7, 2025 | globenewswire.comMaxCyte Expands Stock Capital with New Share IssuanceMay 2, 2025 | tipranks.comBlackRock Adjusts Stake in MaxCyte, Inc.April 22, 2025 | tipranks.comMaxCyte intends to delist from London's AIM to enhance liquidityApril 15, 2025 | lse.co.ukMaxCyte to Delist from AIM, Focus on NasdaqApril 15, 2025 | tipranks.comMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comWith 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsApril 8, 2025 | uk.finance.yahoo.comDown -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)April 8, 2025 | zacks.comDown -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a TurnaroundApril 7, 2025 | zacks.comMaxCyte (MXCT) Upgraded to Buy: Here's What You Should KnowApril 4, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFORA, ARAI, MXCT, and EGHT Company DescriptionsArrive AI NASDAQ:ARAI$7.61 +0.89 (+13.24%) As of 06/18/2025 04:00 PM EasternWe were incorporated on April 30, 2020, in the State of Delaware under the name of Dronedek Corporation. The Company changed its name to Arrive Technology Inc. on July 27, 2023. The Company changed its name to Arrive AI Inc. on September 30, 2024. We are a developmental technology company with a focus on designing and implementing a commercially viable smart mailbox and platform system for smart, secure, and seamless exchange of packages, goods, supplies, food, and medications between people, through the use of robots, and drones. We have not started conducting commercial operations and we had no revenues for fiscal years 2022, 2023 or 2024. Arrive executed an exclusive patent license agreement on May 26, 2020 with its CEO, Mr. O’Toole and amended in December 2024 and March 2025, whereby Mr. O’Toole granted Arrive rights to use, sell, manufacture and otherwise commercialize certain technologies relating to secured drone delivery ALM mailboxes in exchange for license fees. Such technologies helped jumpstart our business operations and will continue to play such a critical role in our growth that we became heavily reliant on the right to use them. Our corporate address is in Fishers, Indiana.8X8 NASDAQ:EGHT$1.84 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.85 +0.01 (+0.54%) As of 06/18/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.8x8, Inc. engages in the provision of enterprise communication solutions. It offers solutions to the business services, education, financial services, government, healthcare, and manufacturing industries. The company was founded in February 1987 and is headquartered in Campbell, CA.Forian NASDAQ:FORA$2.10 +0.04 (+1.94%) As of 06/18/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Forian Inc. provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions. The company's subscription and services-based solutions cover the life sciences, pharma services, and healthcare payer and provider industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania.MaxCyte NASDAQ:MXCT$2.11 -0.04 (-1.86%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.10 0.00 (-0.24%) As of 06/18/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
